Pharmaceutics (Oct 2019)

Strategies for Delivery of siRNAs to Ovarian Cancer Cells

  • Rossella Farra,
  • Matea Maruna,
  • Francesca Perrone,
  • Mario Grassi,
  • Fabio Benedetti,
  • Marianna Maddaloni,
  • Maguie El Boustani,
  • Salvo Parisi,
  • Flavio Rizzolio,
  • Giancarlo Forte,
  • Fabrizio Zanconati,
  • Maja Cemazar,
  • Urska Kamensek,
  • Barbara Dapas,
  • Gabriele Grassi

DOI
https://doi.org/10.3390/pharmaceutics11100547
Journal volume & issue
Vol. 11, no. 10
p. 547

Abstract

Read online

The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery.

Keywords